| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.0K | 21.6% | 60.3% |
| Total Income | 1.1K | 19.8% | 58.6% |
| Expenditure | 1.1K | 30.0% | 53.8% |
| PBT | 93.74 | 259.7% | 265.9% |
| Net Profit | 83.74 | 231.9% | 294.8% |
| OPM | 26.16% | 3.93pp | 10.01pp |
| NPM | 7.97% | 5.09pp | 14.46pp |
| EPS | 3.42 | 180.3% | 94.3% |
Strong presales, weak profit — the H2 presales case hinges on regulatory risk
Q2 delivered presales +109%, but reported PAT of ₹83.7 Cr is inflated by a ₹149 Cr Zentech exit gain. Core profit is soft. H1 presale progress is on track (37.51% of FY27 target), but H2 launches are stalled pending regulatory approvals across Bangalore, Cochin, and Mumbai — the real test is next quarter.
₹2,762 Cr
+109% YoY
₹4,200 Cr
37.51% of ₹11.2K Cr
₹83.7 Cr
+294.8% YoY (includes ₹149 Cr exceptional)
27%
within 25–30% band
₹470 Cr
Q2 alone; FY27 target ₹750 Cr
₹2,500 Cr
+31% YoY
Puravankara delivered a strong operational quarter on presales and collections, and is tracking its full-year guidance on both. But the profit story is weaker than it appears, and the next quarter carries significant regulatory risk.
Where the profit came from
Reported PAT jumped to ₹83.7 Cr, a 294.8% swing from a ₹11 Cr loss in Q2 prior year. On the surface, this looks like a blowout — but the quarter included a ₹149 Cr exceptional gain from the Zentech exit. That means the underlying operational profit is substantially softer. Without the Zentech proceeds, the company would show a significant loss. EBITDA margin of 27% is credible and within the 25–30% guidance band, but the profit-after-tax picture is heavily distorted by the one-timer.
The presale story — on track, but H2 at risk
The real earnings story is presales, not profit. Q2 presales hit ₹2,762 Cr, up 109% YoY. Combined with Q1, H1 presales are ₹4,200 Cr — exactly 37.51% of the FY27 ₹11.2K Cr target. Management maintained guidance, which implicitly requires ₹7,000+ Cr of presales in H2. The company guided to ₹15–16K Cr of launches for H2 to cover this. Collections are strong: ₹2,500 Cr in H1, up 31% YoY, and the presale-to-collection gap is narrowing. All of this tracks.
But here's the catch: multiple H2 launches are stalled at the regulatory approval stage. Bangalore's Winworth-3 project was awaiting RERA approval (flagged as 1–2 weeks away on the call, but timelines are uncertain). Cochin approval was imminent. Cuffe Parade in Mumbai may slip to Q1 FY28. Goregaon redevelopment requires 8–10 months for approval closure. If these slip further, the H2 presale target becomes unachievable, and with it, the FY27 guidance is at risk.
FY27 presales ₹11.2K Cr target maintained
SupportedH1 ₹4,200 Cr = 37.51% achieved; on track. But H2 (₹15–16K Cr launches) is contingent on regulatory approvals, some of which are pending.
EBITDA margin 25–30% band held; Q2 at 27%
SupportedReported EBITDA ₹289 Cr / ₹1,033 Cr revenue = 27.9%. Weighted avg project EBITDA 30% credible. Margin is stable, not expanding.
Debt reduction ₹470 Cr in Q2; FY27 target ₹750 Cr on track
SupportedNet debt reduced ₹470 Cr Q2 alone; ahead of proportional pace. Net leverage at 1.26x still elevated; improving but not fast.
Strong collection momentum, ₹1.3K Cr Q2 up 24% YoY
SupportedH1 collections ₹2,500 Cr up 31%; presale-to-collection gap narrowing. Execution is solid.
H2 presale pipeline ₹15–16K Cr launches planned
OverstatedPipeline cited (12+ South projects, West launches), but several are in regulatory approval pending. Cuffe Parade explicitly may slip to Q1 FY28. Achievable if approvals clear in Nov–Dec, but not assured.
What changed on this call
Presale momentum accelerating (+109% YoY)
Debt trajectory ahead of ₹750 Cr FY27 target
EBITDA margin holding at 27%, not expanding
H2 launch execution deferred; regulatory approvals pending
Zentech exit masks underlying operational profit weakness
The bull-bear ledger
Presales +109% YoY; momentum real and documented
H1 presales 37.51% of FY27 target; on track to deliver
Collections +31% H1; presale-to-collection gap narrowing
EBITDA margin 27% within guidance band; project-level 30% credible
Debt reduction ₹470 Cr ahead of pace; leverage improving
Land platform expanded (H1 ₹14.1K Cr GDV acquisitions); future upside
—
Reported PAT ₹83.7 Cr includes ₹149 Cr Zentech exceptional; core profit weak
H2 launches (₹15–16K Cr presale target) contingent on regulatory approvals, some pending
Net debt still 1.26x equity; refinancing risk if presales disappoint
New market execution risk (NCR, Goregaon redevelopment); 8–10 month approval cycles
Commercial asset leasing (Aerocity, Hebbal) may have timing risk; assumes 6–8 month to 100% occupancy
Stock down 64.74% from ATH, below all key moving averages; street skeptical
Risks, ranked by how much they should concern a holder
H2 launch regulatory approvals pending
HighBangalore Winworth-3, Cochin, Kannkapura RERA all in approval stage. Cuffe Parade explicitly at Q1 FY28 risk. If approvals slip beyond Nov–Dec, the H2 ₹15–16K Cr presale target becomes unachievable, and with it, the FY27 ₹11.2K Cr annual guidance is at risk. This is the single biggest near-term risk.
Earnings quality / exceptional-driven profit
HighReported PAT of ₹83.7 Cr is inflated by ₹149 Cr Zentech exceptional gain. Underlying operational profit is negative. This masks the true profitability of core operations. Future quarters without such exits will show much weaker profits and may reveal a loss-making core business.
Debt leverage at 1.26x equity
MediumDespite ₹470 Cr reduction Q2, net debt of ₹3.76K Cr is still 1.26x equity. The ₹14.1K Cr land acquisitions in H1 require ongoing capex and construction financing. If presales slow or collections disappoint, leverage refinancing risk could rise sharply.
New market execution (NCR, Goregaon)
MediumNCR entry (DMIC Noida) needs 4–6 month approvals (launch Q4 FY27 or Q1 FY28). Goregaon redevelopment needs 8–10 months approval closure. Both are high-opportunity but untested for Puravankara. Execution delays could defer upside and tie up capital.
Commercial asset monetization timing
MediumAerocity leasing target is 6–8 months to 100%; Hebbal capex is ₹450+ Cr over 4 years. If leasing timelines slip, the ₹330 Cr annual rental guidance and debt reduction plans will face pressure.
Residential demand sensitivity to job markets
LowSouth portfolio (Bangalore, Chennai) dependent on IT job growth. Mumbai on affordability. A 5–10% demand softness from macro slowdown is possible but not likely in near term given presale momentum and collections. Long-term risk, not imminent.
How the street is positioned
The stock price of ₹200.84 is down 64.74% from its all-time high of ₹569.6, and is trading below its 20-day, 50-day, and 200-day moving averages — a bearish setup. The RSI of 49.3 is neutral (not oversold). Volume is increasing, suggesting some institutional interest in the weakness.
FII ownership is 16.62% (slightly down from 16.73% prior quarter) and DII is negligible at 0.58%. Promoters hold 75%, a stable anchor. The modest FII trimming — even as the company beats operational targets — suggests institutions are waiting for clarity on H2 execution and the path to normalized (non-exceptional) profitability. The 64.74% drawdown from ATH is significant, but the stock is not yet in oversold territory on technicals, and the street's skepticism on H2 execution risk is understandable.
1 · Nov–Dec 2026 regulatory approvals
Bangalore Winworth-3 RERA, Cochin approval, Kannkapura RERA, and any news on Cuffe Parade will be the near-term catalyst. If these clear in the coming weeks, H2 presale momentum can ramp. If they slip further, the FY27 guidance will be at risk and the stock could re-test lows.
2 · Q3 FY27 presale print
The real test: how much H2 presale momentum actually hits the books. If H2 presales come in >₹6.5K Cr (to hit the FY27 ₹11.2K Cr target), the street will gain confidence. If materially lower, guidance will be under pressure.
3 · Recurring profit guidance / Q3 core earnings
Management should articulate what core/recurring profitability looks like without one-timers. If they can show a path to normalized net margins without asset exits, the earnings quality debate gets resolved. Until then, focus on EBITDA (27%) and presales (+109%) as the real drivers.
Puravankara is executing well on presales and debt — the operational story is sound. But the street's caution is justified: reported profit is inflated by a Zentech windfall, and the FY27 guidance hinges on H2 launches that are contingent on regulatory approvals still pending. The stock's 64% drawdown from ATH is steep, but not yet a compelling turnaround until H2 execution risk is de-risked and core profitability improves.
The number to track from here is not next-quarter profit (it will fluctuate with one-timers), but H2 presales. If the company logs >₹6.5K Cr of presales between now and March 2027, and core EBITDA margins hold at 27%, then the operational story holds and the stock has upside. If H2 presales come in materially short, guidance will miss, and refinancing risk will tighten. The verdict will be written in the presales numbers, not the reported profit.
Strong execution met guidance; debt leverage remains risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
H1 presales on track (37.51% achieved); guidance maintained not raised. Execution strong, targets reachable.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered on guidance: presales ₹2,762 Cr (+109% YoY), EBITDA margin 27% (within 25-30% band), debt reduction ₹470 Cr. H1 presales ₹4,200 Cr = 37.51% of FY27 target, on track. Risk: H2 launches face approval delays (Bangalore, Cochin, Goregaon timelines extended), and net debt 1.26x equity remains elevated.
₹1032.5 Cr
Revenue · +60.3% YoY₹83.7 Cr
Reported PAT · +294.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Presales INR2,762 Cr up 109% YoY
METH1 presales INR4,200 Cr = 37.51% of INR11,200 guidance; on track
EBITDA margin 27%, maintaining 25-30% band
METReported INR289 Cr EBITDA vs INR1,033 Cr revenue = 27.9% ✓; within band
Debt reduction INR470 Cr in Q2
METGross debt INR180 Cr reduction; net debt INR470 Cr reduction ✓
Strong collection momentum, INR1,301 Cr Q2, up 24% YoY
METH1 collections INR2,500 Cr up 31%; presale-to-collection gap narrowing ✓
Multiple launches in H2 for ₹15,000+ Cr presales
OVERSTATEDPipeline cited: 12+ South projects, West launches Pali Hill, Deonar, Cuffe (Q1 FY28 possible), Goregaon 8-10m away
Earnings quality
What changed since the last call
Presale momentum accelerating
UpgradeQ2 presales ₹2,762 Cr up 109% YoY; H1 ₹4,200 Cr vs ₹2,405 Cr prior year. Land platform expanded.
Debt trajectory positive
UpgradeNet debt reduced ₹470 Cr in Q2; trajectory ahead of ₹750 Cr FY27 target. Leverage 1.26x improving.
EBITDA margin holding
Neutral27% in Q2 within 25-30% band; no upside vs prior guidance. Stable, not expanding.
H2 launch execution deferred
DowngradeMultiple projects in approval stage (Bangalore RERA 1-2 weeks, Cochin next, Cuffe Parade risk Q1 FY28). ₹15K presales feasible but tight.
The Q&A
Analysts pressed hard on launch timelines, debt trajectory, and margin profiles. Management held firm on guidance but hedged on specific debt reduction path (growth opportunity trade-off). Some deflection on residential demand (promotional tone on brand resilience). Overall, Q&A was substantive; analysts got answers.
Launch execution & sales — Deepak Purswani, Svan Investments
AnsweredMiami prelaunch (RERA Aug); phenomenal response, ₹1.55L/sq ft ultra-luxury. Equinox 6-tower part of 6,000-unit Bangalore project. Purva Heritage ~30% sold. H2 strong pipeline, 12+ projects South, West launches on track.
Presale-to-collection dynamics — Deepak Purswani, Svan Investments
PartialOperating surplus INR1,000+ Cr mark crossed this quarter. Collections from Zentech exit + project milestones. INR6,000 Cr annual collection target for year.
Debt & capex strategy — Deepak Purswani, Svan Investments
DodgedDebt reduction a choice. ₹400+ Cr reduced Q2; growth is priority. Surplus deployed to acquisitions. Leverage will improve as presales convert.
Geographic expansion — Deepak Purswani, Svan Investments
AnsweredNCR (DMIC, Noida): approvals 4-6 months away, launch likely Q4 FY27 or early Q1. Goregaon: 8-10 months for approvals, then 8-10 months for development closure. Both 33(9) scheme.
Land acquisition & GDV — Rohan Joshi, Eternal Capital
AnsweredINR15,000 Cr GDV acquisition target this year. H1 ₹14,100 Cr already done; growth is the driver, not just debt reduction.
Redevelopment margin targets — Rohan Joshi, Eternal Capital
AnsweredGP >25% baseline; net project margins 22-30% depending on location. South Bombay 30%, suburban 22-25%, greenfield 20%+. Case-by-case evaluation; both purchase & JDA approaches used.
Project-level EBITDA & returns — Sarthak Jain, Individual
AnsweredGP typically >25%; EBITDA 22-30% range. Redevelopment lower initial outlay but location-dependent. All new deals >25% GP; some JDA lower if no capital risk.
Zentech proceeds deployment — Sarthak Jain, Individual
AnsweredINR250 Cr debt repayment, INR250 Cr acquisition spend. Remaining for working capital & project costs. Split reflects both deleveraging & growth.
Commercial asset monetization — Rahul Singh, Eternal Capital
AnsweredAerocity OC received, 100% leasing target 6-8 months. Annuity income model. Hebbal land cost ₹700 Cr for 1.3M sq ft. Capex ₹450+ Cr over 4 years. No major capex for Aerocity.
Commercial annual rental income — Rahul Singh, Eternal Capital
AnsweredINR330 crore annual rental from both Aerocity & Hebbal once 100% leased & operational.
EBITDA margin variance — Deepak Purswani, Svan Investments
AnsweredZentech exceptional item excluded from recurring. Weighted average project EBITDA 30% across projects. Variations by project type (redevelopment lower). Other expense includes approval, marketing, statutory costs by Schedule III.
Residential demand outlook — Deepak Purswani, Svan Investments
PartialSouth driven by job generation; uptick continuing. Mumbai strong; car sales record shows consumer confidence. Brand resilience; 50 years history, diversified developers unlikely to face demand shock despite 5-10% macro noise.
Presale growth drivers — Vishal Singh, Individual
AnsweredCombination: land acquisition, 3 launches, product quality, brand value. Bangalore & Mumbai 2 largest contributors. Strong pipeline for H2. FY28 will be even stronger.
Launch pipeline H2 vs FY28 — Vishal Singh, Individual
AnsweredINR20,000+ total target. At least INR15,000-16,000 this year; FY28 will be more robust. Projects deferred from H2 to Q1 FY28 likely.
Guidance
FY27 presales ₹11,200 Cr target maintained
HighH1 ₹4,200 Cr achieved (37.51%); H2 INR15,000-16,000 Cr launch program + strong new land pipeline.
EBITDA 25-30% band maintained
HighQ2 at 27%; project-level weighted avg 30%. Variations by type (greenfield 28-30%, JDA 22-25%).
Capex pivoting to launches Q2–Q4 FY27
Medium12+ South projects, West launches (Pali Hill, Deonar, Cuffe Parade). Some may slip to Q1 FY28 (approvals pending).
Risks the call surfaced
Execution risk on launches
MediumMultiple H2 projects in approval stage: Bangalore Winworth-3 (RERA 1-2 weeks away), Cochin (next 2-3 days), Kannkapura RERA 1 week away, Cuffe Parade (Q1 FY28 risk). ₹15K presale H2 target tight if delays compound.
Debt leverage
MediumNet debt ₹3,763 Cr, 1.26x equity. ₹14,100 Cr land acquisitions in H1 require ongoing capex & construction financing. Debt-to-equity improvement depends on presale conversion & collection momentum.
New market execution risk
MediumNCR entry (DMIC Noida): approvals 4–6 months away. Goregaon West: 8–10 months regulatory closure. Both high-value markets but execution timelines uncertain. Redevelopment in Mumbai requires tenant management & land assembly complexity.
Commercial asset realization
LowPurva Aerocity & Hebbal expected to generate ₹330 Cr annual rental. Aerocity leasing target 6–8 months; Hebbal capex ₹450+ Cr over 4 years. Delays in leasing would defer cash generation & debt reduction.
Residential demand sensitivity
LowSouth portfolio dependent on job generation; Mumbai/Bangalore on affordability. Potential 5–10% demand softness if economy slows. Brand resilience cited but not quantified.
Management
Score 7/10. Clear on numbers & delivery metrics (presales, collections, margins). Transparent on approval delays & execution challenges. Some promotional tone on demand outlook. Strong H1 track record: 37.51% presales guidance achieved, debt reduction ahead of target, EBITDA margin within band. H2 execution contingent on regulatory approvals.
1 · Nov–Dec 2026
Pali Hill, Winworth-3, Kannkapura RERA approvals & launches
2 · Jan–Mar 2027
H2 project launches; ₹15K+ Cr presales target; debt reduction progress
3 · Q4 FY27
Cuffe Parade possible launch (Q1 FY28 risk); Goregaon 8-10m regulatory closure
Risk: H2 launches face approval delays (Bangalore, Cochin, Goregaon timelines extended), and net debt 1.26x equity remains elevated.